The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification.
Complement activation plays an important role in human pathophysiology. The effect of classical pathway activation is largely dependent on alternative pathway (AP) amplification, whereas the role of AP for the down-stream effect of mannan-induced lectin pathway (LP) activation is poorly understood. In normal human serum specific activation of LP was obtained after exposure to a wide concentration range of mannan on the solid phase. Reaction mechanisms in this system were delineated in inhibition experiments with monoclonal antibodies. Direct mannose-binding lectin (MBL) independent activation of AP was not observed even at high mannan concentrations since addition of the inhibiting anti-MBL mAb 3F8 completely abolished generation of the terminal C5b-9 complex (TCC). However, selective blockade of AP by anti-factor D inhibited more than 80% of TCC release into the fluid phase after LP activation showing that AP amplification is quantitatively responsible for the final effect of initial specific LP activation. TCC generation on the solid phase was distinctly but less inhibited by anti-fD. C2 bypass of the LP pathway could be demonstrated, and AP amplification was also essential during C2 bypass in LP as shown by complete inhibition of TCC generation in C2-deficient serum by anti-fD and anti-properdin antibodies. In conclusion, the down-stream effect of LP activation depends strongly on AP amplification in normal human serum and in the C2 bypass pathway.
Harboe
Morten
M
Institute of Immunology, University of Oslo and Rikshospitalet University Hospital, NO-0027 Oslo, Norway.
Garred
Peter
P
Karlstrøm
Ellen
E
Lindstad
Julie K
JK
Stahl
Gregory L
GL
Mollnes
Tom Eirik
TE
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology; D003175:Complement C2 / Q000276:immunology; D015935:Complement C4b / Q000276:immunology; D011416:Complement Factor D / Q000276:immunology; D015938:Complement Membrane Attack Complex / Q000276:immunology; D003170:Complement Pathway, Alternative / Q000276:immunology*; D006801:Humans; D008297:Male; D008351:Mannans / Q000276:immunology*; D037601:Mannose-Binding Lectin / Q000276:immunology*; D044967:Serum
D000911:Antibodies, Monoclonal; D003175:Complement C2; D015938:Complement Membrane Attack Complex; D008351:Mannans; D037601:Mannose-Binding Lectin; D015935:Complement C4b; D011416:Complement Factor D